Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Traditional Chinese Medicine Holdings Co ( (HK:0570) ) has provided an update.
China Traditional Chinese Medicine Holdings Co. Limited has convened an extraordinary general meeting for 2 February 2026 in Foshan to seek shareholder approval for a series of three-year framework agreements covering financial services, procurement and product supply for the period 2026–2028. The resolutions, if passed, will ratify a financial services framework with Sinopharm Group Finance, as well as master purchase and master supply agreements with China National Pharmaceutical Group Co., Ltd. and its subsidiaries, and will authorise directors to implement these arrangements and make non-material amendments, thereby formalising ongoing related-party transactions that underpin the company’s financing, sourcing of TCM and chemical materials, and sales and leasing activities within the Sinopharm Group.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
More about China Traditional Chinese Medicine Holdings Co
China Traditional Chinese Medicine Holdings Co. Limited is a Hong Kong–incorporated pharmaceutical company focused on the research, production and sale of traditional Chinese medicine and related pharmaceutical products. The group operates primarily in mainland China, supplying TCM formulations and chemical materials through an integrated production and distribution network aligned with the broader Sinopharm ecosystem.
Average Trading Volume: 19,553,164
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.93B
For a thorough assessment of 0570 stock, go to TipRanks’ Stock Analysis page.